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ABSTRACT. Over expression of human GSTA1-1 in tumour cells is part of MDR mechanisms. Substituted 2-hydroxybenzophenones are ubiquitous in naturally 
occurring and synthetic compounds, exhibiting important biological activities. 2,2’-Dihydroxybenzophenones and N-carbonyl analogues, structurally, are ring-
opened forms of xanthone analogues which we reported recently as hGSTA1-1 inhibitors. The present study combined GST inhibition screening, in silico 
molecular docking and enzyme inhibition kinetics, revealing four analogues with strong inhibitory potency (IC50 = 0.18-1.8 μM) and modest cytotoxic activity 
for Caco2 cell line (LC50 = 35 to > 400 μM), thus being useful as lead structures for the design of new inhibitors against hGSTs. 
INTRODUCTION 
Glutathione S-transferases (GSTs, EC 
2.5.1.18) are a family of isoenzymes 
that differ in their tissue-specificity 
expression and distribution. They 
catalyse the conjugation of glutathione 
(GSH) to a variety of hydrophobic 
endogenous and exogenous 
substrates, rendering them 
hydrophilicity and facilitating their 
metabolic processing and eventual 
secretion from the cell [1,2]. Cancer 
cells may acquire resistance by 
overexpressing GST activities, 
hampering the effectiveness of certain 
chemotherapeutic drugs [3,4]. Several 
synthetic drugs and prodrugs 
exhibiting inhibition potency against 
GSTs have been proposed as strategies 
to overcoming MDR attributed to GST 
overexpression [5-9]. We report on the 
synthesis and enzymological study of 
twelve 2,2’-dihydroxybenzophenone 
and N-carbonyl analogues, 5-16, and 
their inhibitory profile vs. hGSTA1-1.  
CHEMISTRY. The synthetic routes 
leading to analogues 5–16 : 
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Figure 1. Purely competitive inhibition kinetics of hGSTA1-1 with inhibitor 
6 using CDNB as a variable substrate. Left: Lineweaver-Burk (primary) plot 
of initial velocities vs [CDNB] at different [inhibitor 6]. Right: secondary 
plot derived from data of the primary plot.  
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Table 1. Inhibition properties for compounds selected 
from screening experiments (‘cherry-picking’) 
against hGSTΑ1-1 activity (IC50) and Caco2 cell 
viability (LC50). 
‘CHERRY-PICKING’ FROM THE LIBRARY OF 2,2’-
DIHYDROXYBENZOPHENONES & N-CARBONYL 
ANALOGUES.  
Compound 
number and 
structure  
Modality of 
inhibition (
a
) 
IC50 against 
hGSTA1-1  
(μΜ) 
LC50 against 
Caco2 cells 
(μΜ) 
5 
OOH OH
 
 
 
 
- 
 
 
- 
 
 
> 400 
6 
OOH OH
 
 
 
 
 
Competitive, 
linear 
 
 
 
1,77 ±  0.10  
 
 
 
31.4 ± 0.4 
8 
OOH OH
Br  
 
 
 
Mixed,  
linear 
 
 
0,24 ± 0.04         
 
 
120 ± 1.9 
11 
 
NOHOH OH
 
 
 
 
- 
 
 
- 
 
 
315 ± 1.4 
14 
NOH OH
NH
CO
 
 
 
 
 
 
Competitive, 
linear 
 
 
 
 
0.33 ± 0.05         
 
 
 
 
87 ± 1.9 
16 
NOH OH
NH
CO
CH3
Br  
 
 
 
 
Mixed, 
hyperbolic 
 
 
 
0.18 ± 0.02 
 
 
 
> 400 
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Inhibitors 8 and 16 bind at a site different that the CDNB-binding 
(catalytic) site, thus showing a mixed modality of inhibition (Figure 3 for 
inhibitor 8). This is in concert with in silico molecular docking, predicting 
that both inhibitors (Figure 4 for inhibitor 8), in their low energy most 
favored position, do not bind to the CDNB-binding site. 
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Figure 3. Mixed inhibition kinetics of hGSTA1-1 with inhibitor 8 using CDNB 
as a variable substrate. Left: Lineweaver-Burk (primary) plot of initial 
velocities vs [CDNB] at different [inhibitor 8]. Right: secondary plot derived 
from data of the primary plot. Points are average of three enzyme assays.  
Figure 2. Substrates CDNB, GSH and inhibitors 6 (left) and 14 (right) at the 
most probable binding sites of hGSTA1-1. All ligands are shown as balls-
and-sticks, except for CDNB which is shown as space filling dot models. 
Both inhibitors (green ligands) partly occupy the catalytic site and clash 
with CDNB when bound at the same site. GSH is depicted in magenta, the 
S atom in yellow, N atoms in blue and O atoms in red. The figure is 
created using the PYMOL v1.4 program.  
ENZYME INHIBITION STUDIES. 
Enzyme inhibition screening revealed two 
2,2’-dihydroxybenzophenones (6 & 8) and 
two N-carbonyl analogues (14 & 16) as 
strong inhibitors against hGSTA1-1 (86-96% 
inhibition).  
 
• Inhibitors 6 and 14 bind at the CDNB-
binding (catalytic) site, showing a purely 
competitive modality of inhibition (Figure 1 
for inhibitor 6). This is in concert with in 
silico molecular docking, predicting that 
both inhibitors (Figure 2), in their low energy 
most favored position, clash with CDNB if 
trying to be accommodated at the site of 
hGSTA1-1 where CDNB binds. 
Figure 4.  Substrates CDNB, GSH and inhibitor 8 at the most probable binding 
sites of hGSTA1-1. All ligands are shown as balls-and-sticks, except for CDNB 
which is shown as space filling dot models. Left: in the absence of CDNB, 
inhibitor 8 (green ligand) is bound close to CDNB-binding region. Right: in 
the presence of CDNB, inhibitor 8 (yellow ligand) is bound close to CDNB, 
developing H-bonds (2.56 and 2.76 Å).  
↓ 
(a)Compounds 6, 8, 14 and 16 showed mixed inhibition modality 
against the co-substrate GSH. 
CONCLUSIONS: We identified analogues with high inhibitory potency 
(IC50 0.18-1.8 μM) and modest cytotoxic activity (LC50 35-400 μM), useful as 
‘lead’ structures in designing new inhibitors and prodrugs for human GSTs. 
